KNOWLEDGE BANK

Interviews

MAb Aggregation: A Problem Within the Biopharmaceutical Industry

Associate Professor, Trinity College Dublin, Ireland
Educated at Seoul National University UC Berkeley and Purdue University with postdoctoral research at the University of Oxford KH Mok specializes in utilising biomolecular NMR spectroscopy to protein foldingmisfoldingaggregation research Coauthor of publications in Nature Nature Communications Nature Immunology PNAS and others he currently serves as a Eureka Independent Evaluation Panel member tec...

Articles

Green Synthesis of Metallic Nanoparticles

Nanotechnology has transformed the pharmaceutical landscape offering revolutionary solutions in drug delivery diagnostics and therapeutics However traditional methods of synthesizing nanoparticles often rely on hazardous chemicals consume high energy and generate toxic byproducts As the industry leans toward sustainable practices green synthesis emerges as a powerful natureinspired alternative Thi...

Research Insights

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

Biopharmaceutical products BPs are widely used to treat autoimmune diseases but immunogenicity limits their efficacy for an important proportion of patients Our knowledge of patientrelated factors influencing the occurrence of antidrug antibodies ADAs is still limited

Case Studies

Quality Management In Clinical Trials: An Observational Case Study By Pfizer

Abstract Clinical trials are conducted to collect the data necessary to provide information for academia industry and regulators to make decisions about the safety and efficacy of the disease illness or preventative medicines under study To ensure investigators are following the protocol complying with regulatory and G

Techno Trends

New Drug Development Workflow Designed for Extrusion-Based Drug Implant Production

The Thermo Scientific Pharma mini implant line first endtoend solution is an automated integrated system designed for continuous production of drug implants Drug formulation scientists can use the first commercially available fully integrated solution for polymerbased drug implant development and production using Hot Melt Extrusion HME to meet growing demand for in...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

2

Trump Tariff Tyranny and Pharma Preparedness

Dr. M Aamir Mirza

Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.

3

Combating the FWA Menace

Ravi Iyer

Ravi Iyer is a visionary and innovative executive with diverse experience in leading and managing product delivery, client implementation, customer service, and operations with direct responsibility for multimillion-dollar budgets. He has extensive experience delivering across multiple disciplines, including Data Management, Data Governance, Cloud Architecture, Advanced Analytics, Master Data Management, Digital Products, and Digital Transformation. Excellent communicator who works collaboratively to deliver technology strategies and value added solutions that meet the needs of all business functions. Ravi is currently the technology executive and Senior Director at Elevance Health Inc.

 

Narasimha Nalamalapu

Narasimha is result driven leader with vast experience in executing various PBM, Health care, Financial, and securities trading applications. Technical expertise in Big data, Cloud, Analytics, Mainframe, BPM, testing, and Data warehouse projects at esteemed organizations like Anthem, Tetrasoft, DST, HCL, Deutsche bank, and Atos Origin. He currently works as Solution Architect at Tetrasoft Inc. Narasimha has vast experience in Pre-sales, Project management, effective customer communication, Architect, Technical Lead, On-site coordinator, and business Analyst roles for various complex assignments across the globe.

 

4

Reshaping the Clinical Trial Model

Anna Hayes

Anna Hayes is a senior data management leader (At Veramed) with nearly 20 years of experience in clinical research. She specializes in biometrics strategy, innovation, and operational excellence, driving smarter oversight and data-driven trial execution. Anna is passionate about integrating people, processes, and technology to future-proof clinical trials and elevate data quality.

5

Nanotechnology Strategies for Age –Related Macular Degeneration

Aira Sarkar

Aira Sarkar is pursuing B. Tech (Pharmaceutical Chemistry and Technology) in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).

 

Sathish Dyawanapelly

Sathish Dyawanapelly is working as an Assistant Professor in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).

 

press releasesRead more...

Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy

Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production

Purdue and Evonik launch strategic partnership in pharmaceutical manufacturing

Purdue University is launching a new industry partnership with Evonik one of the worlds leading specialty chemicals companies The partnership agreement lays the groundwork for sponsored research product and technology development manufacturing collaboration and workforce and economic development

Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals

Genomics a scienceled Techbio company using largescale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development today announced a fouryear extension of its longstanding drug target discove

22nd Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech

Pharma organisations are still in a transition process from traditional model centered on blockbuster to more collaborative global ones In order to address the main challenge of RD productivity PPM professional serve as a link between operational teams and senior management level They have the role...

Takeda and Zuellig Pharma Announce Strategic Regional Collaboration to Expand Patient Access to Takeda's Innovative Medicines Across Southeast Asia

Takeda and Zuellig Pharma today announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutions across Malaysia Indonesia and the Philippines Effective December the collaboration

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease

Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg

Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments

Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC

Erasca Enters into Collaboration with Bristol Myers Squibb to Evaluate Pancreatic Cancer Therapy

Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers to evaluate the combination of ERAS and navlimetostat BMS an investigational PRMT inhibitor in patients with pancreatic cancer

OBI Pharma and Novartis Partner to Develop Next-Generation ADCs for Cancer Treatment

OBI Pharma has entered into a collaboration and licensing agreement with Novartis to develop nextgeneration antibodydrug conjugates ADCs using novel payloads and OBIs proprietary technology platforms